Gene therapy hope for ALS patients in early trial
NCT ID NCT07169175
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing a new gene therapy called SNUG01 for people with ALS, a disease that damages nerves controlling movement. The study will involve 21 adults and aims to check if the treatment is safe and tolerable. Researchers will also look for early signs that it might help slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SNUG01 (gene therapy using a harmless virus to deliver a therapeutic gene)
- What this could lead to
- If successful, this could point toward a treatment that slows or stops the progression of ALS, a devastating nerve disease.
- What could go wrong
- This is a very early, small trial (21 people) focused on safety, not proof of effectiveness. Gene therapies can have unexpected side effects, and the benefit may be minimal or absent.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350000, China
-
Massachusetts General Hospital
Boston, Massachusetts, 02467, United States
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100000, China
-
Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Custom-Made genetic drug slow ALS?
- Can a One-Time gene shot calm inflammation in ALS?
- Can filtering the blood slow ALS in people with a troubling antibody?
- Blood test may slash ALS diagnosis time from months to days
- Custom gene silencer takes aim at a rare form of ALS
- Could a gentle brain ZAP help ALS patients breathe easier?